INTRODUCTION
============

Striatin and caveolin-1 (cav-1), which are scaffolding/regulating proteins in various tissues, play roles in modulating cellular function through multifunctional signals \[[@B1][@B2]\]. In humans and rodents, single nucleotide polymorphic variants of the gene coding for striatin are associated with salt-sensitive high blood pressure \[[@B3]\]. Therefore, striatin is thought to be present in the kidney. Unfortunately, studies of striatin related to kidney function have not been reported. The cav-1 protein promotes renal water and salt reabsorption via modulation of sodium-chloride cotransporter function and regulation of vascular endothelial nitric oxide \[[@B4]\].

Aldosterone, a hormone produced by zona glomerulosa cells of the adrenal cortex, regulates sodium, potassium, and acid-base balance, principally in the kidney \[[@B5]\]. In addition to genomic action, which occurs via the aldosterone-mineralocorticoid receptor (MR) complex, aldosterone can also act through rapid (≤30 minutes) non-genomic mechanisms that are mediated by MR, or possibly through a membrane- associated pathway \[[@B6][@B7][@B8][@B9][@B10]\]. This non-genomic process is insensitive to transcription or translation inhibitors \[[@B6][@B7][@B8][@B9][@B10]\].

MR is localized in epithelial cells of the kidney and gut, and is also found in non-epithelial cells such as neurons and vascular smooth muscle cells \[[@B11]\]. MR has been shown to interact with several proteins, including striatin and cav-1 \[[@B2]\]. A previous *in vitro* study showed that striatin interacted with MR in mouse aortic endothelial cells, human endothelial cells, and mouse heart tissue \[[@B12]\]. Both *in vitro* and *in vivo* investigations have demonstrated that aldosterone increased striatin protein abundance, with a peak at 6 hours and a return to baseline after 12 hours. This effect was found to be inhibited by an MR antagonist \[[@B12]\]. A recent *in vitro* study reported that striatin was essential in mediating rapid responses to aldosterone \[[@B13]\]. A previous examination of mouse heart tissue found support for the interplay between cav-1 and MR in modulating the mechanisms of aldosterone action \[[@B14]\]. In cultured human umbilical vein endothelial cells, aldosterone incubation for 48 hours induced abundant cav-1 levels \[[@B15]\]. In this regard, aldosterone and MR in the kidney might contribute to the aforementioned effects of both proteins.

Currently, no *in vivo* data exist on the effects of aldosterone on striatin and cav-1 levels in rat kidney tissue. The present study was conducted to investigate the rapid actions of aldosterone on striatin and cav-1 levels and localization in rat kidney tissue by Western blot analysis and immunohistochemistry, respectively. The role of MR in this relationship was also investigated.

METHODS
=======

Animals
-------

Male Wistar rats aged 6 to 8 weeks that weighed 200 to 240 g and were pathogen-free were obtained from the National Center of Scientific Use of Animals, Mahidol University, Nakornpathom, Thailand. The rats were housed in a room with a controlled temperature (23℃±1℃) and a 12-hour light/dark cycle. The animals were fed regular rat chow (dry pellets) and tap water *ad libitum* \[[@B16][@B17][@B18][@B19]\]. The rats were acclimatized for 3 days before starting the experiment. All animal protocols were approved by the Ethics Committee of Research, Chulalongkorn University (Permit number IRB 019/2560). The serum creatinine level of each rat was required to be \<1 mg/dL \[[@B16][@B17][@B18][@B19]\].

Experimental design
-------------------

The rats were divided into three main groups: sham, aldosterone (Aldo), and eplerenone (Ep.)+Aldo (*n*=6/group). The groups were defined as follows: (1) sham: rats received normal saline solution (NSS) (0.5 mL/kg body weight \[BW\]) by an intraperitoneal injection; (2) Aldo: rats received an intraperitoneal injection of aldosterone (150 µg/kg BW; diluted in NSS); (3) Ep.+Aldo: rats received an intraperitoneal injection of eplerenone (an MR blocker) at a dose of 15 mg/kg BW diluted in dimethyl sulfoxide 30 minutes before the aldosterone injection. This dose of aldosterone was chosen because it was previously used in studies quantifying levels of protein kinase C alpha (PKCα); α1-Na^+^, K^+^-ATPase; PKCβ (I and II), and Na^+^/H^+^ exchanger proteins (1 and 3) \[[@B18][@B19]\]. Therefore, in the present investigation, we further examined the effect of this dose on striatin and cav-1 levels.

On the day of the experiment, 30 minutes after the NSS or aldosterone injection, rats were anesthetized with an intraperitoneal injection of thiopental (100 mg/kg BW) \[[@B17][@B18][@B19]\]. Plasma samples obtained from the abdominal aorta were stored at −80℃ until use for aldosterone level measurements by a radioimmunoassay kit (Aldo-Riact, CIS Bio International, Gif-sur-Yvette, France). Blood and urine chemistry were measured by an indirect method (Model CX3, Beckman, Krefeld, Germany). The kidneys were removed, and half of each kidney was fixed in liquid nitrogen and then stored at −80℃ until use for the measurement of striatin and cav-1 levels by Western blot analysis. The other half of the renal tissue was fixed in 10% paraformaldehyde, subjected to tissue processing by an automated tissue processor (Shandon Citadel 2000, Thermo Scientific, Rockford, IL, USA), and embedded in paraffin wax for localization of these proteins by immunohistochemistry \[[@B17][@B18][@B19]\].

Western blot analysis
---------------------

Electrophoresis and immunoblotting were performed as previously described \[[@B17][@B18][@B19]\]. Renal tissue samples were homogenized on ice with a homogenizer (IKA, T25 Basic, Selangor, Malaysia) in homogenizing buffer (20 mM Tris-HCl; pH 7.5, 2 mM MgCl~2~, 0.2 M sucrose, and 5% \[v/v\] protease inhibitor cocktail; Sigma-Aldrich, St. Louis, MO, USA). Homogenate samples were subjected to a serial centrifugation to yield plasma membranes \[[@B17][@B18][@B19]\]. Proteins from the plasma membrane (80 to 200 µg) were mixed with sample buffer. Proteins (striatin, cav-1, and β-actin) were then resolved using 8% to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotted onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). The membranes were incubated with a primary monoclonal antibody to striatin (6: sc-136084; 1:500; Santa Cruz Biotechnology, Dallas, CA, USA) \[[@B20]\], cav-1 (7C8: sc-54564; 1:500; Santa Cruz Biotechnology) \[[@B21]\], or β-actin (Santa Cruz Biotechnology), followed by the respective horseradish peroxidase-linked secondary antibody (Bio-Rad). Immunoreactive proteins were detected by enhanced chemiluminescence (SuperSignal West Pico kit, Thermo Fisher Scientific Inc., Waltham, MA, USA) and documented using a molecular imager ChemiDoc XRS system (Bio-Rad). Each intensity band was quantified using a High Resolution UV and White Light Gel Doc System linked to a computer analysis system (Quantity One version 4.2, Bio-Rad). The intensity ratio of each studied protein to β-actin was calculated.

Immunohistochemistry
--------------------

Detection of protein localization was performed as previously described \[[@B17][@B18][@B19]\]. Paraffin-embedded kidney tissues were cut to 4-µm-thick sections for examination of striatin and cav-1. Tissue sections were mounted on 3-aminopropyltriethyloxy-saline coated slides (Sigma-Aldrich) and then deparaffinized in xylene and alcohol, with endogenous peroxidase activity quenched in 3% hydrogen peroxide for 10 minutes. The non-specific binding of antibody was blocked by incubating tissue sections with 5% normal horse serum (Vector Laboratory, Burlingame, CA, USA) in phosphate buffer solution (PBS-T) (PBS+0.1% Tween) for 30 minutes at room temperature. The sections were further incubated in primary antibody against striatin (1:1,000), or cav-1 (1:1,000) for over 1 hour at room temperature, followed by biotinylated goat anti-mouse-rabbit immunoglobin (Vector Laboratory) for 60 minutes at room temperature. After incubation, tissue sections were rinsed twice for 10 minutes with PBS-T and once for 10 minutes in PBS, and then reacted with ABC-streptavidin horseradish peroxidase complex (Vector Laboratory) for 60 minutes at room temperature. After washing, the slides were reacted for peroxidative activity in 3,3′-diaminobenzidine solution (Sigma-Aldrich) and counterstained with hematoxylin (CV Laboratories, Bangkok, Thailand). As a negative control, the primary antibody was omitted, resulting in negative staining. Three blinded investigators independently examined and scored the intensity of staining on a semi-quantitative five-tiered grading scale from 0 to 4 (0=negative; 1=trace; 2=weak; 3=modmoderate; 4=strong) as previously described \[[@B17][@B18][@B19]\].

Statistical analysis
--------------------

The biochemical results and protein levels of striatin and cav-1 were expressed as mean±standard deviation. The statistical significance of differences between groups were assessed by analysis of variance with a *post hoc* comparison by the Tukey test when appropriate. The median staining intensity scores of renal striatin and cav-1 proteins were presented as previously described \[[@B17][@B18][@B19]\]. The Kruskal-Wallis test was used to analyze differences in the median staining intensity scores of the studied proteins among the three groups (sham, Aldo, and Ep.+Aldo). All statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA). *P* values less than 0.05 were considered to indicate statistical significance.

RESULTS
=======

Blood and urine biochemical data
--------------------------------

As shown in [Table 1](#T1){ref-type="table"}, plasma aldosterone levels were significantly higher in the Aldo group than in the sham group (sham: 1,315.11±10.22 pmol/L; Aldo: 6,234.33±92.88 pmol/L, *P*\< 0.001; Ep.+Aldo: 6,288.55±87.47, *P*\<0.001). There were no significant changes in the levels of any plasma parameters among all studied groups. Neither aldosterone nor eplerenone significantly altered the ratio of plasma sodium to potassium or the ratio of urinary sodium to potassium when compared with the sham group ([Table 1](#T1){ref-type="table"}).

Aldosterone enhanced renal striatin and cav-1 levels
----------------------------------------------------

By Western blot analysis ([Fig. 1](#F1){ref-type="fig"}), the levels of striatin (110 kDa) and cav-1 (22 kDa) were assessed. Aldosterone significantly elevated the levels of striatin and cav-1 by 149%±9% (*P*\<0.05) and 211%±10% (*P*\<0.001) compared to the sham group, respectively. Eplerenone had no significant effect on striatin levels (140%±7%, *P*\<0.05 vs. sham, *P*=1.00 vs. Aldo). The increase in cav-1 protein induced by aldosterone was partially blocked by eplerenone, decreasing from 211%±10% to 149%±8% (*P*\<0.05 vs. sham and vs. Aldo).

Aldosterone activated renal striatin protein localization
---------------------------------------------------------

Localization of striatin in the cortex in the sham group is demonstrated in [Table 2](#T2){ref-type="table"}, [Fig. 2B](#F2){ref-type="fig"}. Immunoreactivity was trace in the glomerulus (GL), proximal convoluted tubule (PCT), distal convoluted tubule (DCT), and peritubular capillary (Pcap). The staining score was weak in the cortical collecting duct (CCD). Aldosterone increased the intensity score in the GL, CCD, and Pcap to moderate levels ([Fig. 2C](#F2){ref-type="fig"}), whereas immunoreactivity in the PCT and DCT remained weak. Eplerenone reduced the aldosterone-induced increases in the intensity score only in the GL and CCD ([Fig. 2D](#F2){ref-type="fig"}).

In the outer medulla (OM), aldosterone elevated the intensity score from 3 to 4 in the vasa recta (VR) ([Table 2](#T2){ref-type="table"}, [Fig. 2G](#F2){ref-type="fig"}). Staining in the thick ascending limb of the loop of Henle (TALH), medullary collecting duct (MCD), and thin limb of the loop of Henle (tLH) did not change. Surprisingly, staining intensity scores in all studied areas increased even when pretreatment with eplerenone was applied ([Fig. 2H](#F2){ref-type="fig"}).

In the inner medulla (IM), immunoreactivity was enhanced by aldosterone to strong levels in the MCD and VR, whereas the intensity score in the tLH increased to moderate ([Fig. 2K](#F2){ref-type="fig"}). Eplerenone had no inhibitory effect on the immunoreactivity induced by aldosterone in all studied areas ([Fig. 2L](#F2){ref-type="fig"}).

[Table 3](#T3){ref-type="table"} shows the *P* values obtained by the Kruskal-Wallis test when comparing the median intensity scores of striatin levels among the three treatment groups (sham, Aldo, and Ep.+Aldo) in rat kidney tissue.

Aldosterone altered renal cav-1 localization
--------------------------------------------

Localization of cav-1 in the cortex in the sham group is shown in [Table 2](#T2){ref-type="table"}, [Fig. 3B](#F3){ref-type="fig"}. Immunoreactivity was trace in the GL and moderate in the Pcap, and no staining was noted in the PCT, DCT, and CCD. Aldosterone increased immunoreactivity in the GL and Pcap to strong, whereas immunostaining in the PCT, DCT, and CCD remained at trace levels ([Fig. 3C](#F3){ref-type="fig"}). Eplerenone only reduced the staining score in the GL to moderate ([Fig. 3D](#F3){ref-type="fig"}).

In the OM, aldosterone elevated the intensity score to weak in the TALH, MCD, and tLH ([Fig. 3G](#F3){ref-type="fig"}). These changes were inhibited by pretreatment with eplerenone ([Fig. 3H](#F3){ref-type="fig"}). The intensity score in the VR remained strong in all groups ([Fig. 3G, H](#F3){ref-type="fig"}). In the IM, aldosterone increased the immunoreactivity to a strong level in the VR, but it decreased to a trace level in the tLH ([Fig. 3K](#F3){ref-type="fig"}). Eplerenone had no inhibitory effect on immunoreactivity induced by aldosterone in the VR ([Fig. 3L](#F3){ref-type="fig"}). By contrast, the staining intensity score in the tLH was increased by pretreatment with eplerenone ([Fig. 3L](#F3){ref-type="fig"}). The intensity score in the MCD remained at a trace level in all groups ([Fig. 3K, L](#F3){ref-type="fig"}).

The differences in median intensity scores of cav-1 levels were significant (*P*\<0.05) by the Kruskal-Wallis test, as shown in [Table 3](#T3){ref-type="table"}.

DISCUSSION
==========

The present results provide the first *in vivo* data simultaneously showing renal striatin and cav-1 levels and immunoreactivity 30 minutes following aldosterone administration. Aldosterone significantly enhanced the renal abundance of striatin by 50%, and pretreatment with an MR antagonist, eplerenone, did not reverse that effect ([Fig. 1](#F1){ref-type="fig"}). Previous *in vitro* and *in vivo* investigations have demonstrated that aldosterone increases striatin abundance, with a peak at 6 hours and a return to baseline after 12 hours \[[@B12]\]. Studies in human and mouse endothelial cells have revealed that striatin is a critical mediator of the rapid actions of aldosterone \[[@B13][@B22]\].

The precise mechanism through which aldosterone increases striatin levels has not been established. An explanation for this may be that Akt signaling induced by aldosterone enhances striatin levels. In cardiomyocytes, aldosterone provided a biphasic effect on Akt phosphorylation at either a short time (10 minutes) or a longer time (24 hours) \[[@B23]\]. In endothelial cells, another steroid hormone (17β-estradiol, E2) increased striatin levels via the Akt pathway \[[@B24]\]. In this regard, the aldosterone-induced striatin levels in the present study may reflect the involvement of Akt signaling. In addition, E2-induced striatin expression in vascular smooth muscle cells has been shown to be related to the activation of extracellular signal-regulated kinases 1/2 (ERK1/2) \[[@B25]\]. In an *in vivo* study, we previously showed that aldosterone injection increased ERK1/2 phosphorylation in rat kidney tissue at a 30-minute interval \[[@B16]\]. Therefore, we propose that the rapid aldosterone-induced increase in striatin levels in the rat kidney is mediated via ERK1/2 activation. In addition, a previous *in vitro* study in a human endothelial cell line showed that aldosterone-induced increases in striatin levels were reversed by an MR blocker, spinorolactone \[[@B12]\]. By contrast, our present study in rat kidney tissue revealed that striatin levels remained high despite pretreatment with an MR antagonist, eplerenone ([Fig. 1](#F1){ref-type="fig"}). This discrepancy may be due to tissue-specific differences in responses. Further *in vivo* investigations are required to elucidate this issue. Thus, in the kidney, the aldosterone-induced increase in striatin levels is an MR-independent pathway.

For cav-1, the present data show that aldosterone rapidly doubled cav-1 levels in rat kidney ([Fig. 1](#F1){ref-type="fig"}). In a previous study, aldosterone incubation induced abundant levels of cav-1 in endothelial cells \[[@B15]\]. In liver sinusoidal endothelial cells, aldosterone treatment increased membrane levels of cav-1 \[[@B26]\]. The mechanism by which aldosterone increases caveolin levels may be related to Src activation. In M-1 cell, aldosterone rapidly induced Src protein levels in a dose-dependent manner \[[@B27]\]. Furthermore, the abundance of Src in vascular smooth muscle cells was increased by aldosterone in a time-dependent manner (from 15 to 45 minutes) \[[@B28][@B29]\]. It has been noted that Src tyrosine kinases induce caveolin phosphorylation \[[@B30]\]. The aldosterone-induced increase in cav-1 levels in the present study may be linked to Src activation. More *in vivo* studies exploring this issue are needed. In addition, incubation with PKCα increased cav-1 protein abundance in human lung fibroblasts \[[@B31]\]. Moreover, we documented that aldosterone rapidly enhanced PKCα levels in rat kidney tissue \[[@B18]\]. Therefore, on the basis of the present findings, we suggest that aldosterone induces higher levels of cav-1 through PKCα activation. Of note, a previous *in vitro* study in vascular endothelial cells reported that aldosterone-induced changes in cav-1 levels were partially inhibited by an MR blocker, spironolactone \[[@B15]\]. In the present study, we used eplerenone since it has a greater selectivity for MR than spironolactone \[[@B32]\]. Eplerenone was also able to partially attenuate the aldosterone-induced increase in cav-1 levels in rat kidney tissue ([Fig. 1](#F1){ref-type="fig"}). This suggests that aldosterone regulates cav-1 levels, in part, through the MR pathway.

In the rapid non-genomic pathway, protein levels are actually not increased by synthesis of new molecules \[[@B9][@B10]\]. The higher levels of striatin and cav-1 in the present study may have resulted from stimulation of existing inactive proteins by various kinase enzymes, such PKC and ERK1/2. This possibility has been extensively documented in previous studies by many investigators, as well as in our experiments showing that aldosterone rapidly increased protein levels \[[@B9][@B10][@B16][@B17][@B18][@B19]\].

No previous data are available regarding the immunolocalization of striatin in rat kidney tissue. In Madin-Darby canine kidney cells, striatin was expressed in the cytosolic compartment and plasma membrane \[[@B33]\]. In canine cardiac myocytes, striatin was localized within the intercalated discs \[[@B34]\]. The present study is the first to document the distribution of striatin in kidney tissue. In sham rats, prominent immunoreactivity was noted in the medulla region, especially in the MCD and VR ([Table 2](#T2){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}). Aldosterone rapidly increased immunostaining in most studied areas. Pretreatment with eplerenone attenuated the intensity scores in the cortex region, but immunoreactivity in the tLH and MCD was progressively enhanced. The mechanism underlying this phenomenon remains to be clarified. In the present study, cav-1 immunoreactivity showed a similar baseline distribution as in previous investigations \[[@B35][@B36]\]. As shown in [Fig. 3](#F3){ref-type="fig"}, cav-1 immunostaining induced by aldosterone was obvious in the vasculature including the GL, Pcap, and VR ([Table 2](#T2){ref-type="table"}). The staining intensity scores in the GL, TALH, MCD, and tLH were slightly reduced by eplerenone. The distribution of striatin and cav-1 induced by the rapid action of aldosterone along nephron segments was found to show diverse patterns, implying that both proteins play significant roles in the kidney.

Of note, striatin and cav-1 are involved in modulating various cellular functions through multifunctional signals \[[@B1][@B2]\]. The critical role in striatin on salt-sensitive blood pressure and vascular responses has been clearly documented \[[@B3][@B37][@B38]\]. Unfortunately, studies of striatin related to kidney function have not been conducted. Meanwhile, cav-1 modulates health and disease through a wide range of mechanisms \[[@B39]\]. An *in vivo* study suggested that cav-1 regulates aldosterone-mediated pathways of glucose and lipid homeostasis \[[@B40]\]. Aldosterone-induced oxidation promoting cell defenestration takes place in cav-1-related autophagy \[[@B26]\]. In the kidney, cav-1 promotes renal water and salt reabsorption by modulating sodium-chloride cotransporter function and regulating vascular endothelial nitric oxide \[[@B4]\]. More *in vivo* studies are needed to elucidate the molecular mechanisms of striatin and cav-1 in modulating aldosterone pathways and, consequently, in regulating kidney function.

In conclusion, this is the first *in vivo* study to demonstrate that aldosterone rapidly enhances renal striatin and cav-1 levels. Aldosterone increases striatin levels by an MR-independent pathway, whereas cav-1 is partially regulated through MR.
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![Effects of aldosterone on renal striatin and caveolin-1 (cav-1) protein levels. Representative Western blot analysis of renal striatin and cav-1 protein levels in the sham, aldosterone (Aldo), and eplerenone and aldosterone (Ep.+Aldo) groups (*n*=6/group). Histogram bars show the densitometric ratios of striatin or cav-1 to β-actin intensity. Data are expressed as mean±standard deviation of six independent experiments. ^a^*P*\<0.05; ^b^*P*\<0.001 vs. sham; ^c^*P*\<0.05 vs. Aldo.](enm-34-291-g001){#F1}

![Effects of aldosterone on renal striatin localization. Representative immunohistochemical staining micrographs of renal striatin in the cortex (A--D), the outer medulla (E--H), and the inner medulla (I--L) from the sham (B, F, J), aldosterone (Aldo) (C, G, K), and eplerenone and aldosterone (Ep.+Aldo) (D, H, L) groups (*n*=6/group). Negative controls: A, E, I (A--D, ×400; E--L, ×200). GL, glomerulus; Pcap, peritubular capillary; DCT, distal convoluted tubule; PCT, proximal convoluted tubule; CCD, cortical collecting duct; tLH, thin limb of the loop of Henle; VR, vasa recta; TALH, thick ascending limb of the loop of Henle; MCD, medullary collecting duct.](enm-34-291-g002){#F2}

![Effects of aldosterone on renal cav-1 localization. Representative immunohistochemical staining micrographs of renal cav-1 in the cortex (A--D), the outer medulla (E--H), and the inner medulla (I--L) from the sham (B, F, J), aldosterone (Aldo) (C, G, K), and eplerenone and aldosterone (Ep.+Aldo) (D, H, L) groups (*n*=6/group). Negative controls: A, E, I (A--D, ×400; E--L, ×200). CCD, cortical collecting duct; Pcap, peritubular capillary; PCT, proximal convoluted tubule; GL, glomerulus; DCT, distal convoluted tubule; tLH, thin limb of the loop of Henle; MCD, medullary collecting duct; VR, vasa recta; TALH, thick ascending limb of the loop of Henle.](enm-34-291-g003){#F3}

###### Blood and Urine Chemistry in the Experimental Groups

![](enm-34-291-i001)

  Variable                               Sham             Aldo                Ep.+Aldo
  -------------------------------------- ---------------- ------------------- -------------------
  Plasma aldosterone, pmol/L             1,315.11±10.22   6,234.33±92.88^a^   6,288.55±87.47^a^
  Plasma sodium, mmol/L                  141.32±1.48      142.17±6.32         140.22±4.82
  Plasma potassium, mmol/L               3.53±0.22        3.58±0.26           3.49±0.28
  Plasma chloride, mmol/L                102.64±1.34      102.31±2.91         102.42±2.62
  Plasma bicarbonate, mmol/L             24.71±1.14       24.29±1.58          24.48±1.64
  Plasma creatinine, mg/dL               0.24±0.02        0.24±0.02           0.24±0.03
  Blood urea nitrogen, mg/dL             19.22±1.64       20.48±3.28          20.25±2.68
  Ratio of plasma sodium to potassium    41.27±3.64       39.87±2.94          40.38±2.87
  Ratio of urinary sodium to potassium   0.32±0.02        0.32±0.02           0.32±0.03

Values are expressed as mean±standard deviation.

Aldo, aldosterone; Ep., eplerenone (*n*=6/group).

^a^*P*\<0.001 compared with the sham group.

###### Median Staining Intensity Scores of Renal Striatin and Caveolin-1 Localization

![](enm-34-291-i002)

                  Striatin   Caveolin-1               
  --------------- ---------- ------------ --- --- --- ---
  Cortex                                              
   GL             1          3            2   1   4   3
   PCT            1          2            2   0   1   1
   DCT            1          2            2   0   1   1
   CCD            2          3            2   0   1   1
   Pcap           1          3            3   3   4   4
  Outer medulla                                       
   TALH           2          2            3   1   2   1
   MCD            2          2            4   1   2   1
   VR             3          4            4   4   4   4
   tLH            3          3            4   0   2   1
  Inner medulla                                       
   MCD            3          4            4   1   1   1
   VR             3          4            4   2   4   4
   tLH            2          3            4   2   1   2

Staining intensity: 0, negative, no reactivity; 1, trace, faint or pale brown staining with less membrane reactivity; 2, weak, light brown staining with incomplete membrane reactivity; 3, moderate, shaded of brown staining of intermediate darkness with usually almost complete membrane reactivity; 4, strong, dark brown to black staining with a usually complete membrane pattern, producing a thick outline of the cell \[[@B17][@B18][@B19]\].

Aldo, aldosterone; Ep., eplerenone (*n*=6/group); GL, glomerulus; PCT, proximal convoluted tubule; DCT, distal convoluted tubule; CCD, cortical collecting duct; Pcap, peritubular capillary; TALH, thick ascending limb of the loop of Henle; MCD, medullary collecting duct; VR, vasa recta; tLH, thin limb of the loop of Henle.

###### Kruskal-Wallis Analysis of Median Staining Intensity Scores of Striatin and Caveolin-1 among the Three Treatment Groups in Rat Kidney Tissue

![](enm-34-291-i003)

  Areas            Mean rank   *P* value          
  ---------------- ----------- ----------- ------ ------------
  Striatin                                        
   Cortex                                         
    GL             3           12.6        8.4    0.002^a^
    PCT            4.2         10.6        9.2    0.029^a^
    DCT            3           10          11     0.005^a^
    CCD            5.8         12.4        5.8    0.011^a^
    Pcap           3           10.5        10.5   0.004^a^
   Outer medulla                                  
    TALH           5.9         5.9         12.2   0.015^a^
    MCD            5.5         5.5         13     0.004^a^
    VR             5           9.5         9.5    0.024^a^
    tLH            5           7.4         11.6   0.024^a^
   Inner medulla                                  
    MCD            3.8         10.1        10.1   0.015^a^
    VR             5           9.5         9.5    0.001^a^
    tLH            3           9           12     0.003^a^
  Cav-1                                           
   Cortex                                         
    GL             3           12.6        8.5    0.002^a^
    PCT            3           10.5        10.5   0.001^a^
    DCT            3           10.5        10.5   0.001^a^
    CCD            3           10.5        10.5   0.001^a^
    Pcap           3           10.5        10.5   0.001^a^
   Outer medulla                                  
    TALH           5.5         13          5.5    0.001^a^
    MCD            5.5         13          5.5    0.001^a^
    VR             8           8           8      1.000 (NS)
    tLH            3           13          8      0.001^a^
   Inner medulla                                  
    MCD            8           8           8      1.000 (NS)
    VR             3           10.5        10.5   0.001^a^
    tLH            13          5.5         5.5    0.001^a^

Aldo, aldosterone; Ep., eplerenone (*n*=6/group); GL, glomerulus; PCT, proximal convoluted tubule; DCT, distal convoluted tubule; CCD, cortical collecting duct; Pcap, peritubular capillary; TALH, thick ascending limb of the loop of Henle; MCD, medullary collecting duct; VR, vasa recta; tLH, thin limb of the loop of Henle; NS, non-significant (*n*=6/group).

^a^*P*\<0.05.
